Sign up
Pharma Capital
EPIC: PYC
Market: AIM
52-week High/Low: 13.30p / 3.52p
Sector: Health Care, Equipment & Services
Market Cap: 2.99M

Physiomics is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company uses a combination of industry standard and its own proprietary Virtual Tumour modelling technologies to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The...

Physiomics Plc

www.physiomics-plc.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Physiomics Plc

Physiomics Plc Snapshot

Services

Services

Project examples:

  • Predicting inhibition ratios for compounds with >1 target
  • Mechanistic modelling to validate targets and predict effects of candidate drugs
  • Pathway models to understand detailed mechanism of action

Project examples:

  • Ranking compounds and schedules for development progression
  • Determining optimal biologically effective dose in mice or humans
  • Optimising regimes for dose and timing to achieve maximal efficacy Optimising regimes to delay emergence of resistance
  • Translation to and optimisation of regimes for new indications
  • Predicting effects of radiation/ drug combinations
  • Predicting effects of immune and traditional therapy combinations

 

Our Team

Dr Paul Harper, Chairman

Dr Paul Harper, Chairman

Dr Paul Harper has over 35 years’ experience in the life sciences industry covering both drug development and medical devices. He is an NED of Reneuron Holdings plc, an AIM quoted company.  In addition, he is an adviser to the Board of CamStent Ltd. Paul has served as Chairman of Oval Medical Technologies and of Sareum plc, Chief Executive of Cambridge Antibody Technology Limited, and founded Provensis Limited. He has also served as Corporate Development Director of Unipath Limited, then the medical diagnostics business of Unilever PLC, and as Director of Research and Development for Johnson & Johnson Limited. Formerly head of Antimicrobial Chemotherapy for Glaxo PLC, Paul has a PhD in Molecular Virology and is the author of over 50 publications.

Dr Jim Millen, Chief Executive Officer

Dr Jim Millen, Chief Executive Officer

Jim joined Physiomics in April 2016, bringing over 15 years’ experience in pharmaceuticals and biotechnology gained at a number of blue chip global companies as well as smaller UK-based organisations. At Allergan, Jim was responsible for corporate development in its Europe, Africa and Middle East region where he was pivotal in expanding the company’s geographical footprint before moving to a senior role responsible for commercial strategy and market access. Prior to that, at GSK, Jim held business development roles of increasing responsibility including within the company’s innovative Centre of Excellence for External Drug Discovery. In the last 18 months Jim has supported a number of smaller companies in fund raising and strategic partnering activities. Over the course of his career he has completed an array of deals worth many hundreds of millions of dollars, spanning licencing, acquisition, divestment, development and commercialisation.

Jim studied medicine at Queens’ College, Cambridge University and qualified as a doctor from the London Medical School. He holds an MBA from INSEAD.

Dr Christophe Chassagnole, Chief Operating Officer

Dr Christophe Chassagnole, Chief Operating Officer

Dr Christophe Chassagnole has been involved in systems biology and bio-computing projects since the mid-nineties, with experience in both academic and industrial environments. His Doctorate was achieved at the Victor Segalen-Bordeaux II University, and then he held a post doctorate position with IBVT at Stuttgart University. Before Joining Physiomics Dr Chassagnole worked in France as a senior researcher for CRITT Bio-Industries (Toulouse) for 3 years. He joined Physiomics in May 2004 as project leader to develop the model portfolio of the company. He was appointed Chief Operating Officer of Physiomics in May 2007.

Anthony Clayden, Head of Finance

Anthony Clayden, Head of Finance

Anthony Clayden is a Finance Director and Company Secretary with over 16 years’ experience directing or advising over 30 high growth potential businesses of differing size and complexity and brings broad experience of strategic, operational and financial matters.  His career encompasses a number of businesses in the life sciences and healthcare sector including 6 years as Chief Financial Officer of AIM quoted Futura Medical plc where he was involved in its IPO and a series of placings. Previously, Anthony worked with KPMG and PwC on a range of corporate finance matters including fundraisings, company sales and acquisition advice. Anthony has a B.Sc. (Hons) in Natural Sciences from Durham University and is a Qualified Chartered Accountant.

 

Share Information

Physiomics is listed on the AIM market under symbol PYC. Please click on the London Stock Exchange symbol to view recent share price and other market information.

“Trade mark of London Stock Exchange plc”

Physiomics shares are not traded on any other exchanges and there is no restriction on the transfer of shares. The total number of ordinary shares in issue is: 71,910,394.

Not in public hands: 63.95% of which 62.60% are held in nominee accounts.

Significant Shareholders as at 7th June 2018

Investor Name Holding
Interactive Investor Services 23.20%
Hargreaves Lansdown (Nominees) 17.17%
Barclays Direct Investing Nominees 11.75%
HSDL Nominees Limited 10.49%
Peel Hunt Holdings Limited 7.99%
Vidacos Nominees 3.50%
HSBC Client Holdings Nominee (UK) 3.44%

 

Document Last Updated: 7th June 2018

+44 (0)1865 784980

[email protected]

[email protected]

Magdalen Centre
Oxford Science Park
Oxford
OX4 4GA
UK

Auditors

 

Shipleys LLP
Registered Auditors
Chartered Accountants
10 Orange Street
London WC2H 7DQ
www.shipleys.com

Registrars

 

Link Asset Services
The Registry
34 Beckenham Rd
Beckenham
Kent BR3 4TU
www.linkassetservices.com

Broker

 

Hybridan
20 Ironmonger Lane
London
EC2V 8EP
www.hybridan.com

Nominated Advisor

 

WH Ireland
11 St James’s Square
Manchester
M2 6WH
www.wh-ireland.co.uk

Solicitors

 

Taylor Vinters LLP
Merlin Place
Milton Road
Cambridge
CB4 0DP
www.taylorvinters.com

This part of the website has been designed to comply with the requirements of Rule 26 of the AIM Rules for Companies – ‘Company information disclosure’.

Document last updated 7th June 2018.

Registration

Physiomics plc is incorporated in, and operates from, the UK. Physiomics plc is registered in England and Wales.

Company Number
4225086

Registered Office
The Magdalen Centre Oxford Science Park Oxford OX4 4GA UK.

VAT Number
GB 778 7496 48 Physiomics plc commenced trading on July 26 2001. The Company listed on the London Alternative Investment Market in December 2004 under the symbol PYC.

This part of the website has been designed to comply with the requirements of Rule 26 of the AIM Rules for Companies – ‘Company information disclosure’.

View full PYC profile View Profile
View All

Market Reports Including PYC

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.